George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.40
Bid: 29.40
Ask: 31.40
Change: 0.00 (0.00%)
Spread: 2.00 (6.803%)
Open: 30.40
High: 30.40
Low: 30.40
Prev. Close: 30.40
MIG5 Live PriceLast checked at -
Maven Income and Growth VCT 5 is an Investment Trust

To invest in a diversified portfolio of later-stage UK private companies to provide long-term capital appreciation and generate maintainable levels of income for shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of Auditor

4 Oct 2022 15:30

RNS Number : 7583B
Maven Income & Growth VCT PLC
04 October 2022
 

MAVEN INCOME AND GROWTH VCT PLC (Maven VCT), MAVEN INCOME AND GROWTH VCT 3 PLC (Maven VCT 3), MAVEN INCOME AND GROWTH VCT 4 PLC (Maven VCT 4), and MAVEN INCOME AND GROWTH VCT 5 PLC (Maven VCT 5); (each a Company and together the Companies) 

Change of Auditor

Following a formal tender process, the Companies are pleased to announce the appointment of Johnston Carmichael LLP (Johnston Carmichael) as its new Auditor with effect from 4 October 2022. Johnston Carmichael will conduct the audit of each Company's financial statements for their current financial years, which are to 30 November 2022 for Maven VCT 3 and Maven VCT 5; 31 December 2022 for Maven VCT 4; and 28 February 2023 for Maven VCT. The appointment of Johnston Carmichael as Auditor for each Company's subsequent financial year will be subject to approval by Shareholders at their next respective Annual General Meetings, all to be held in 2023.

In accordance with Section 519 of the Companies Act 2006, the Company's previous Auditor, Deloitte LLP (Deloitte), has deposited a statement with each of the Companies of the circumstances connected with them ceasing to hold office as Auditor of the Companies (the Statement). Each Statement confirms that Deloitte resigned as Auditor of the relevant Company because they considered that the fee was uneconomic, given the effort required to conduct the audit. Copies of the Statements will be sent to every person who is entitled to receive a copy of each Company's Annual Reports and Financial Statements.

The Boards of the Companies wish to take this opportunity to extend their appreciation and gratitude to Deloitte for the services rendered to the Companies during its respective periods of tenure.

Issued on behalf of the Companies

Maven Capital Partners UK LLP, Secretary

4 October 2022

Enquiries: 

Graeme Cullen, Maven Capital Partners UK LLP:

Tel: +44 (0) 141 206 0110

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPGBPUUPPGCC
Date   Source Headline
26th Apr 20242:44 pmRNSUnaudited NAV - Dividend Investment Scheme
23rd Apr 20242:27 pmRNSResult of AGM
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:49 pmRNSIssue of Equity
27th Mar 202410:31 amRNSIssue of Equity
22nd Mar 20244:25 pmRNSStatement re Offer for Subscription
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:48 pmRNSUnaudited Net Asset Value
8th Mar 20242:57 pmRNSAnnual Financial Report
15th Feb 20244:45 pmRNSTransaction in Own Shares
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:12 amRNSIssue of Equity
7th Feb 20243:09 pmRNSDividend Declaration
19th Dec 20233:28 pmRNSIssue of Equity
18th Dec 20235:24 pmRNSUnaudited Net Asset Value
9th Nov 20233:51 pmRNSResult of General Meeting
20th Oct 20234:13 pmRNSTransaction in Own Shares
13th Oct 20234:56 pmRNSPublication of a Prospectus
4th Oct 20234:03 pmRNSNet Asset Value(s)
29th Aug 20239:15 amRNSDirectorate Change
24th Jul 202311:16 amRNSHalf-year Report
21st Jul 20234:43 pmRNSTransaction in Own Shares
21st Jul 20239:48 amRNSIssue of Equity
17th Jul 202310:57 amRNSNet Asset Value - Dividend Investment Scheme
11th Jul 20234:47 pmRNSNet Asset Value
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
14th Jun 202310:33 amRNSDividend Declaration
2nd Jun 20239:48 amRNSIssue of Equity
5th May 202310:23 amRNSIssue of Equity - Dividend Investment Scheme
27th Apr 20233:57 pmRNSTransaction in Own Shares
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
26th Apr 202311:39 amRNSNet Asset Value - Dividend Investment Scheme
25th Apr 20233:14 pmRNSNet Asset Value(s)
25th Apr 202312:50 pmRNSResult of AGM
5th Apr 202312:32 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
23rd Mar 20235:18 pmRNSAnnual Financial Report
3rd Mar 20239:56 amRNSIssue of Equity
21st Feb 20234:44 pmRNSTransaction in Own Shares
8th Feb 202310:24 amRNSDirector/PDMR Shareholding
8th Feb 20239:48 amRNSIssue of Equity
1st Feb 20233:25 pmRNSUnaudited NAV and Proposed Final Dividend
9th Nov 20223:02 pmRNSResult of General Meeting
4th Nov 20223:25 pmRNSTransaction in Own Shares
26th Oct 20223:53 pmRNSTransaction in Own Shares
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor
4th Oct 20221:35 pmRNSNet Asset Value(s)
26th Aug 202210:14 amRNSIssue of Equity
22nd Aug 20229:36 amRNSStatement re Dividend Investment Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.